Vyloo
Dr Reddy's Laboratories Ltd

Zytorvi 240mg Injection

ContainsToripalimab (240mg)
℞
Prescription Required
Store between 2°C to 8°C
MRP₹1,17,187.0020% OFF
₹93,749.60

Inclusive of all taxes

Packaging:injection of 6ml solution
Zytorvi 240mg Injection

Free Express Cold-Chain Delivery

Temperature-controlled dispatch across India within 4 to 24 hours.

Composition:Toripalimab (240mg)
Manufacturer:Dr Reddy's Laboratories Ltd
Licensed Network
Store between 2°C to 8°C
Rx Verification
Express Dispatch

Financial Assistance Available

PAP Scheme Available

Manufacturer patient assistance program (PAP) available for Zytorvi 240mg Injection. Eligible patients can access subsidized treatment schemes.

WhatsApp Check PAP Eligibility

About this medicine

Zytorvi 240mg Injection (Toripalimab (240mg))is a prescription oncology medicine. Below is educational product information — follow your doctor's advice for dose and use.

Zytorvi 240mg Injection is a prescription immunotherapy medication used to treat nasopharyngeal carcinoma, a rare cancer located in the upper throat behind the nose, by helping the body's immune system target and combat cancerous cells. Administered exclusively by healthcare professionals in a clinical setting, it can be used alone or combined with other therapies, making regular attendance at all scheduled appointments essential since missing a dose can reduce its overall effectiveness. Common side effects include fatigue, hypothyroidism, and joint or muscle pain, which should be reported to a doctor if they persist so that management strategies can be provided. Before starting treatment, patients must disclose all pre-existing medical conditions and current medications to avoid harmful interactions, and the drug must be strictly avoided by pregnant or breastfeeding women due to severe risks to the developing child.

Quick Facts

Chemical ClassPeptides
Habit FormingNo
Therapeutic ClassANTI NEOPLASTICS
Action ClassOther Anticancer Agents

Generic Name

Toripalimab (240mg)

Dosage Form

Solution

Prescription Status

Doctor's Rx Required

Uses of Zytorvi 240mg Injection

Treatment of Relapsed and refractory Nasopharyngeal carcinoma

Side Effects of Zytorvi 240mg Injection

Oncology medicines should be administered strictly under medical supervision. Inform your oncologist immediately if you experience adverse symptoms.

Fatigue
Hyperthyroidism
Musculoskeletal (bone, muscle or joint) pain

Clinical Safety Advice for Zytorvi 240mg Injection

Follow expert clinical guidelines regarding interactions, precautions, and medical conditions when taking Zytorvi 240mg Injection.

Alcohol
CONSULT YOUR DOCTOR

It is not known whether it is safe to consume alcohol with Zytorvi 240mg Injection. Please consult your doctor.

Pregnancy
UNSAFE

Zytorvi 240mg Injection is highly unsafe during pregnancy. It can cause serious harm to the unborn baby, including birth defects and pregnancy loss. Do not use this medicine if you are pregnant or planning to become pregnant.

Breast Feeding
CONSULT YOUR DOCTOR

Information regarding the use of Zytorvi 240mg Injection during breastfeeding is not available. Please consult your doctor.

Driving
UNSAFE

Zytorvi 240mg Injection may decrease alertness, affect your vision, or make you feel sleepy and dizzy. Do not drive if these symptoms occur.

Kidney
CAUTION

Zytorvi 240mg Injection should be used with caution in patients with severe kidney disease. Dose adjustment may be needed.

Liver
SAFE IF PRESCRIBED

Zytorvi 240mg Injection is probably safe to use in patients with liver disease. Limited data suggest dose adjustment may not be needed.

Cold-Chain Temperature Protocol

Temperature-controlled cold-chain dispatch for Zytorvi 240mg Injection across India, with express delivery in Delhi NCR, Noida, and Ghaziabad.

2°C - 8°C Guaranteed

Temperature Monitoring

Sourced from certified cold-storage warehouses.

Insulated Transit

Dispatched in gel-ice thermal insulated boxes.

Rx Verification

Prescription validated prior to cold dispatch.

Frequently Asked Questions

Zytorvi is an immunotherapy medicine containing Toripalimab (240 mg/6 mL). It belongs to a class of medications called immune checkpoint inhibitors (anti-PD-1 monoclonal antibodies).

It is primarily indicated for the treatment of Nasopharyngeal Carcinoma (NPC), a type of head and neck cancer located behind the nose: In combination with chemotherapy (cisplatin and gemcitabine) for first-line treatment of recurrent or metastatic advanced NPC. As a single agent (monotherapy) for recurrent or metastatic NPC that has progressed after platinum-based chemotherapy.

Toripalimab targets and blocks the PD-1 receptor on T cells. Cancer cells frequently exploit the PD-1 pathway to avoid detection. By blocking this pathway, Zytorvi reactivates the patient's immune system, empowering T cells to recognize and destroy cancer cells.

Zytorvi is administered as an intravenous (IV) infusion under the supervision of a qualified medical oncologist or oncology nurse in a specialized clinical setting. It must never be taken orally or self-injected.

Common side effects include fatigue, musculoskeletal pain, rash, nausea, loss of appetite, and thyroid abnormalities (such as hypothyroidism or hyperthyroidism).

Because Zytorvi stimulates the immune system, it can occasionally cause immune cells to attack normal organs. These immune-mediated reactions can affect the lungs (pneumonitis), liver (hepatitis), bowels (colitis/severe diarrhea), kidneys, or hormone glands. Report symptoms like persistent cough, shortness of breath, severe diarrhea, or sudden vision/endocrine changes to the treating oncologist immediately.

If an infusion appointment is missed, contact the oncology care team as soon as possible to reschedule. Do not attempt to take a double dose or compress treatment cycles without direct physician instructions.

No. Toripalimab can cause fetal harm. Women of reproductive potential should confirm they are not pregnant before beginning treatment and must use effective contraception during treatment and for at least 4 months after the final dose. Breastfeeding is not recommended during this period.

Vials must be stored refrigerated between 2°C and 8°C (36°F to 46°F) in their original packaging to protect them from light and moisture. Do not freeze and do not shake the vial.

Have questions about your cancer prescription?

Our licensed oncology pharmacists are available to assist with medicine availability, cold-chain handling, and prescription verification.

WhatsApp Chat on WhatsApp Call 9220172920